FSM Wealth Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 70.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,521 shares of the biopharmaceutical company's stock after acquiring an additional 11,766 shares during the period. FSM Wealth Advisors LLC's holdings in Pfizer were worth $720,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the business. Capital Advisory Group Advisory Services LLC lifted its position in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares during the period. Citizens National Bank Trust Department lifted its position in Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock worth $1,118,000 after buying an additional 395 shares during the period. Trust Co of the South raised its holdings in shares of Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after purchasing an additional 441 shares during the period. Charter Oak Capital Management LLC raised its holdings in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after purchasing an additional 444 shares during the period. Finally, Ballentine Partners LLC grew its holdings in shares of Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock worth $2,260,000 after purchasing an additional 458 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Stock Performance
Shares of Pfizer stock opened at $24.60 on Thursday. The firm has a market cap of $139.89 billion, a price-to-earnings ratio of 13.09, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The stock's 50-day moving average is $24.88 and its 200-day moving average is $24.13. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer's payout ratio is currently 91.49%.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on PFE shares. UBS Group restated a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $28.13.
Read Our Latest Stock Report on PFE
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
